Literature DB >> 18052813

Situating end-of-life decision making in a hybrid ethical frame.

Ellen Barton1.   

Abstract

Good communication in EOL (end-of-life) discussions is described at a general level in the literature, but there are few studies of EOL discussions at the level of interaction, with data drawn from the actual talk between physicians and families. In this article I present a discourse analysis of EOL discussions from an American ICU (intensive care unit) where the decision to withdraw life support is situated in a hybrid ethical frame co-constructed as the final phase of the EOL discussion. In Mishler's (1984) terms, the final phase of the EOL discussion merges the voice of medicine and the voice of the lifeworld, with both physicians and families initiating, developing, and repeating particular topics that encompass not only the logistics of death but also the ethics of the end-of-life decision. Physicians index their ethical accountability in terms of medical futility, and families express their accountability in terms of an ethics of consciousness. The hybrid ethical frame that is co-constructed ultimately centers upon consensus that the 'right' decision has been made from both ethical perspectives.

Entities:  

Mesh:

Year:  2007        PMID: 18052813     DOI: 10.1515/CAM.2007.017

Source DB:  PubMed          Journal:  Commun Med        ISSN: 1612-1783


  2 in total

1.  Accounting for medical communication: parents' perceptions of communicative roles and responsibilities in the pediatric intensive care unit.

Authors:  Cynthia Gordon; Ellen Barton; Kathleen L Meert; Susan Eggly; Murray Pollacks; Jerry Zimmerman; K J S Anand; Joseph Carcillo; Christopher J L Newth; J Michael Dean; Douglas F Willson; Carol Nicholson
Journal:  Commun Med       Date:  2009

2.  Communication between healthcare professionals and relatives of patients approaching the end-of-life: A systematic review of qualitative evidence.

Authors:  Rebecca J Anderson; Steven Bloch; Megan Armstrong; Patrick C Stone; Joseph Ts Low
Journal:  Palliat Med       Date:  2019-06-11       Impact factor: 4.762

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.